NIDA-Funded Pain Management Research Halted by Regulatory Action
What happened
Research funded by the National Institute on Drug Abuse identified compounds, including SR-17018, that can relieve pain in mice without causing respiratory depression. While the drug was previously available online and showed promise in resetting tolerance in opioid-dependent mice, clinical trials were halted after the US Drug Enforcement Admin took action against the compound.
From wired.com
Why it matters
The discovery addresses the opioid crisis by offering a potential alternative to traditional pain medications. However, the regulatory action by the US Drug Enforcement Admin creates a significant barrier for the future development and approval of this type of pain management drug.
From wired.com
Who's involved
- National Institute on Drug AbuseFunded the research into safer pain management options.
- Laura BohnResearcher who filed a patent on the promising compound SR-17018.
- FDAGovernment organization involved in drug approval pathways.
- Food and Drug AdministrationGovernment organization in Thailand involved in drug approval pathways.
- Danelle Stevens-WatkinsResearcher who received funding from the National Institute on Drug Abuse.
- Omeros CorporationCompany receiving financial funding from the National Institute on Drug Abuse.
- Ensysce BiosciencesCompany receiving grant funding from the National Institute on Drug Abuse.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
National Institute on Drug Abuse
branch of the National Institutes of Health in the United States
Nothing else this week.